Clinical trial · Observational
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Myeloproliferative Neoplasm | Myeloproliferative Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Describe the epidemiological characteristics of the study population
- timeFrame
- at enrollment
- description
- Description of MPN subtypes according to age
- measure
- Describe the mutational landscape of these MPNs
- timeFrame
- at enrollment
- description
- Rate of mutations JAK2/CALR/MPL
Secondary outcomes (3)
- measure
- Describe the classical MPN (Myeloproliferative neoplasia) outcomes-1
- timeFrame
- At 10 years
- description
- Incidence of thrombosis
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Patient diagnosed with non-LMC MPN before the age of 30 (PV or TE or MFP or PreMF) according to the 2016 WHO criteria. * Signature of the consent form for participation in the FIMBANK project. * Agreement to participate in the VYP study. * Patient of legal age at the time of inclusion in VYP. * Patient affiliated to a social security scheme Exclusion Criteria: * Refusal to participate by patients of full age * Patient under legal protection (guardianship, curatorship, etc.)
References
Publications (0)
Data not yet available